Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-037385
Filing Date
2021-07-19
Accepted
2021-07-19 08:32:43
Documents
3
Period of Report
2021-07-19

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea144393-6k_nlspharm.htm 6-K 16073
2 NLS PHARMACEUTICS ANNOUNCES THE APPOINTMENT OF ERIC KONOFAL, M.D., PH.D. AS CHIE ea144393ex99-1_nlspharm.htm EX-99.1 18108
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3401
  Complete submission text file 0001213900-21-037385.txt   39974
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 211096926
SIC: 2834 Pharmaceutical Preparations